RS did the statistical analysis and made illustrations
and graphs. SZ did histological analysis of tumor and tissue samples. MS helped with cell culture, western blot and mice studies. HK designed the study, carried out the experiments, wrote the manuscript and provided selleck compound guidance at every step of the study. All authors have read and approved the final manuscript.”
“Background Bacillus thuringiensis (Bt) is a gram positive, facultative aerobic and spore-forming bacteria. It produces parasporal inclusions containing various insecticidal delta-endotoxins during its sporulative phase and has been used in agricultural fields as an insecticide for decades [1, 2]. Recently, it has been found that parasporal proteins of Bt exhibit cytotoxic effect on human cancer cells [3–5]. In
2000, the word parasporin was first introduced by Mizuki et al. to describe bacterial parasporal proteins capable of discriminatively killing cancer cells [6]. To date, four classes of parasporins have been selleck kinase inhibitor identified, namely parasporin 1 (PS1), parasporin 2 (PS2), parasporin 3 (PS3) and parasporin 4 (PS4) [7]. Though many studies have been carried out to characterise these parasporins and to investigate their mechanism of action on human cancer cell lines, little is known about the cancer cell-killing mechanism and the receptors to which these proteins bind on cancer selleck chemical cells. This is especially true for PS3 and PS4 [7]. Previously we demonstrated that purified Bacillus thuringiensis (Bt) 18 toxin, from Bt 18, a Malaysian isolate, was selectively cytotoxic against CEM-SS but not human T lymphocytes and was non-haemolytic [8]. We hypothesised Immune system that the toxin binds to a specific receptor on CEM-SS and that it
competes with commercially available anticancer drugs for the receptor. This study was therefore conducted to further investigate the binding affinity of the toxin for CEM-SS, its interaction with other Bt toxins and commercially available anticancer drugs for binding sites on CEM-SS and to localise where the toxin binds to the cells. Since leukaemia is a common and deadly disease, there is an urgency to develop new and more efficient treatment methods to deal with the problem. Purified Bt 18 toxin used in this study represents a good potential therapeutic agent as it is selectively cytotoxic to CEM-SS, non-cytotoxic to human T lymphocytes and non-haemolytic. These properties of purified Bt 18 toxin may allow it to be used as part of a combination therapy on top of current anticancer drugs, thus lowering the dose required for these drugs. This study shows that purified Bt 18 toxin binds on the cell surface of CEM-SS and its mechanism of cell death may differ from that of Btj toxin, Bt 22 toxin and the selected anticancer drugs since it did not significantly compete with these compounds for the same binding site. Methods Bacillus thuringiensis culture, activation and purification Bacillus thuringiensis was grown to induce sporulation in conditions described by Nadarajah et al.